



Multimeric Biotherapeutics, Inc.
("MultimericBio")
"Unlocking the potential of the TNF SuperFamily Ligands"

Multimeric Biotherapeutics announces the issuance of a key patent in Europe

Jul. 22, 2009, San Diego, CA – The European Patent Office (EPO) has announced the issuance of a key patent for Multimeric Biotherapeutics, Inc. The patent is entitled, "Multimeric Forms of TNF SuperFamily Ligands," and is designated as EP1235853B1. This patent protects the company's key composition-of-matter technology for producing ligands in the TNF SuperFamily as highly active, soluble, many-trimer ligands. The lead molecule is UltraCD40L, a four-trimer version of CD40 ligand (CD40L), one of the most powerful molecules made by the immune system. UltraCD40L is currently being developed as a vaccine adjuvant capable of rescuing vaccines that would otherwise be too weak to be effective. The molecule also has significant potential for stimulating the immune system to recognize and resist the growth of tumors.

With the issuance of this European patent, the company's intellectual property portfolio now dominates in Europe as it already does in the U.S. This is important since Europe comprises 41% of the world pharmaceutical market.

For further details, visit the company's website: www.multimericbio.com

About Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics, Inc. is a biotech company focused on applying CD40L and other TNF SuperFamily ligands for the prevention and treatment of disease. It uses its novel technology to create next-generation vaccines and tumor immunotherapies. More information is available at www.multimericbio.com. Contact us at info@multimericbio.com